<DOC>
	<DOCNO>NCT02536937</DOCNO>
	<brief_summary>Primary Objective : To study effect mild , moderate , severe renal impairment pharmacokinetics ( PK ) eliglustat . Secondary Objective : To assess tolerability eliglustat tartrate give single dose subject mild , moderate , severe renal impairment comparison match subject normal renal function .</brief_summary>
	<brief_title>A Study Effects Renal Impairment Pharmacokinetics Tolerability Eliglustat Tartrate</brief_title>
	<detailed_description>The total study duration screen period approximately 31 day . In stage 1 , subject severe renal impairment normal renal function enrol . Subjects mild moderate renal impairment may enrol stage 2 result subject severe renal impairment show substantial effect reduce renal function pharmacokinetics .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>Inclusion criterion : For renal impaired : Male female subject , 18 79 year age , inclusive . Body weight 50.0 kg 125.0 kg inclusive male , 40.0 kg 110.0 kg inclusive female , body mass index ( BMI ) 18.0 37.0 kg/m^2 , inclusive . Stable chronic renal impairment , define CockroftGault formula . For severe renal impairment : CrCl &lt; 30 mL/min . For moderate renal impairment : 30 mL/min ≤CrCl &lt; 50 mL/min . For mild renal impairment : 50 mL/min ≤CrCl ≤80 mL/min . For matched subject : Male female subject , 18 79 year inclusive , matched age . Body weight within 15 % body weight subject renal impairment match BMI 18.0 37.0 mg/kg^2 inclusive . Matched cytochrome P450 ( CYP ) 2D6 predict phenotype base genotype . Certified healthy comprehensive clinical assessment ( detailed medical history complete physical examination ) . For healthy subject : CrCl &gt; 80 mL/min . Exclusion criterion : For renal impairment patient : Uncontrolled clinically relevant cardiovascular , pulmonary , gastrointestinal , metabolic , hematological , neurological , psychiatric , systemic , ocular , gynecologic ( female ) infectious disease , sign acute illness . Active hepatitis , hepatic insufficiency . Acute renal failure ( de novo superimpose preexist chronic renal impairment ) , nephrotic syndrome . History current hematuria urologic origin limit subject 's participation study . Subjects require dialysis study . Presence history drug hypersensitivity , allergic disease diagnose treated physician . If female , pregnancy ( define positive betahuman chorionic gonadotropin [ βhCG ] blood test ) , breastfeed . Any significant change chronic treatment medication within 14 day inclusion . Pgp inhibitor and/or inducer , CYP2D6 and/or CYP3A inducer , strong and/or moderate CYP2D6 and/or CYP3A inhibitor . Up one weak CYP2D6 inhibitor and/or one weak CYP3A inhibitor allow ( define The Metabolism Transport Drug Interaction Database™ ( DIDB ) . Positive result follow test : antihuman immunodeficiency virus 1 2 antibody ( antiHIV1 antiHIV2 Ab ) . Preexisting cardiac disease ( current congestive heart failure , recent acute myocardial infarction , bradycardia , heart block , ventricular arrhythmia ) , long QT syndrome , use Class IA ( eg , quinidine , procainamide ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medication . Any subject CYP2D6 indeterminate ultrarapid metabolizer ( URM ) phenotype . For matched volunteer : Any history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic , hematological , neurological , osteomuscular , articular , psychiatric , systemic , ocular , gynecologic ( female ) , infectious disease , sign acute illness . Presence history drug hypersensitivity , allergic disease diagnose treated physician . If female , pregnancy ( define positive βhCG blood test ) , breast feeding . For subject 50 year old : medication ( include St John 's Wort ) within 14 day inclusion , within 5 time elimination halflife pharmacodynamic halflife medication , whichever long , exception hormonal contraception menopausal hormone replacement therapy ; vaccination within last 28 day , biologics ( antibody derivative ) within 4 month inclusion . For subject 50 year old : significant change chronic treatment medication within 14 day inclusion . Pgp inhibitor and/or inducer , CYP2D6 and/or CYP3A inducer , strong and/or moderate CYP2D6 and/or CYP3A inhibitor . Up one weak CYP2D6 inhibitor and/or one weak CYP3A inhibitor allow ( define The Metabolism Transport Drug Interaction Database™ ( DIDB ) . Positive result follow test : hepatitis B surface antigen ( HBsAg ) , antihepatitis C virus ( antiHCV ) Ab , antiHIV1 antiHIV2 Ab . Preexisting cardiac disease ( current congestive heart failure , recent acute myocardial infarction , bradycardia , heart block , ventricular arrhythmia ) , long QT syndrome , use Class IA ( eg , quinidine , procainamide ) Class III ( eg , amiodarone , sotalol ) antiarrhythmic medication . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>